Treatment of multiple sclerosis comprising DHODH inhibitors

US11877994B2 · kind B2 · utility

Assignee

• IMMUNIC AG · DE

Inventors

• Andreas Muhler · Oderberg, DE
• Hella KOHLHOF · Munich, DE
• Daniel VITT · Germering, DE

Key dates

• Filing date: Aug 2, 2021
• Grant date: Jan 23, 2024
• Expiry date: Sep 28, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating or ameliorating multiple sclerosis by the dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus or a pharmaceutically acceptable salt and/or a solvate, in particular a hydrate, thereof or a solvate, in particular a hydrate, of a pharmaceutically acceptable salt thereof, by administering to a human patient a therapeutically effective amount of the DHODH inhibitor, more specifically a daily dose of about 10 mg to about 45 mg.